Study Summary
This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).
Want to learn more about this trial?
Request More InfoInterventions
single dose of CNCT19BIOLOGICAL
Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously.
Lymphodepletion treatment:
Drugs:Fludarabine Drugs: Cyclophosphamide
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The Second Hospital of Anhui Medical University | Hefei | Anhui | China |
| Children's Hospital of Chongqing Medical University | Chongqing | Chongqing Municipality | China |
| Guangzhou Women and Children's Medical Center | Guangzhou | Guangdong | China |
| Nanfang Hospital | Guangzhou | Guangdong | China |
| Union Hospital Tongji Medical College Huazhong University of Science of Technology | Wuhan | Hubei | China |
| Children's Hospital of Nanjing Medical University | Nanjing | Jiangsu | China |
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou | Jiangsu | China |
| The First Affilicated Hospital of Nanchang University | Nanchang | Jiangxi | China |
| Institute of Hematology & Blood Diseases Hospital | Tianjin | Tianjin Municipality | China |